The average quantity of negotiated antitumor drugs in Chinese hospitals increased by 15%, and the accessibility of drugs improved significantly
2021-05-02
"In 2020, according to data monitoring network monitoring in the hospital is equipped with negotiations than the previous year, the number of antineoplastic drugs on average increased by 15%, the average hospitalized patients with a 6% increase in the number of people using these drugs, and the cost of all time is decreased by 8%, some of the more expensive immunotherapy drugs, targeted therapy time costs fell by 50% - 70%. As a result, the availability of anti-tumor drugs has significantly improved." "To strengthen the overall medical code of conduct by monitoring the rational behavior of cancer diagnosis and treatment and the rational use of anti-tumor drugs. For example, in 2020, when we looked at the hospitals we were monitoring, we found that the gold standard for the pathology of patients on antitumor drugs had improved by 6 percent over the previous year, which means it's becoming more standard."
"Of course, at different levels and different types of hospitals, there will be differences in the allocation of anti-tumor drugs and the level of use of anti-tumor drugs because of the different levels of hospitals and the different levels of doctors, so there will be some differences. We are gradually making up for this weakness through homogenization, like the quality control we just mentioned." "Hejer added.
He Jie said that in the future, the National Cancer Center will continue to monitor the clinical application of anti-tumor drugs, analyze, evaluate and improve the use of key drugs, better guide the clinical allocation and use of anti-tumor drugs, and provide a reference for the assessment of various medical institutions by the National Health Commission.
"Of course, at different levels and different types of hospitals, there will be differences in the allocation of anti-tumor drugs and the level of use of anti-tumor drugs because of the different levels of hospitals and the different levels of doctors, so there will be some differences. We are gradually making up for this weakness through homogenization, like the quality control we just mentioned." "Hejer added.
He Jie said that in the future, the National Cancer Center will continue to monitor the clinical application of anti-tumor drugs, analyze, evaluate and improve the use of key drugs, better guide the clinical allocation and use of anti-tumor drugs, and provide a reference for the assessment of various medical institutions by the National Health Commission.